Upfront Briefing
Pfizer reloads its oncology pipeline with a $10.5B licensing pact with Innovent — 12 early-stage programs, a $650M upfront, and a deal timed to the opening day of ASCO 2026. Elsewhere, SHINE picked up European marketing authorisation for Ilumira, healthcare finally led the tape, and ASCO opens today in Chicago — bringing the sector's most closely watched oncology data week, with ivonescimab OS, Revolution Medicines' daraxonrasib Phase 3 plenary (May 31), and Merck's sac-TMT ADC among the must-watch readouts.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,563.6 |
0.6% |
10.3% |
| Nasdaq 100 |
30,223.9 |
0.8% |
19.9% |
| Russell 2000 |
2,936.6 |
0.6% |
17.1% |
| Healthcare (XLV) |
150.9 |
1.4% |
(3.0%) |
| Biotech (XBI) |
136.0 |
1.1% |
11.9% |
| Nasdaq Biotech (NBI) |
5,995.9 |
1.1% |
5.1% |
| Clinical Trials (BBC) |
43.7 |
0.3% |
16.1% |
|
- Healthcare led every major sector — XLV +1.4%, XBI +1.1% — as the Pfizer/Innovent $10.5B oncology pact and the opening of ASCO 2026 in Chicago delivered a dual sector catalyst that drew both large-cap pharma and biotech flows.
- The broader tape was carried by reports of a U.S.-Iran 60-day ceasefire extension easing Strait of Hormuz risk and pulling crude lower, while AI names (Microsoft, Oracle, Palantir +3–4%) added a tech tailwind; April PCE printing at 3.8% — its highest in nearly three years — was shrugged off.
- Market data: U.S. cash close Thursday, 28 May 2026.
The Big 3
|
1
|
Pfizer, Innovent strike $10.5B cancer pipeline deal
|
- Antibody-drug conjugates and multi-specific antibodies are at the center here: Pfizer will pay Innovent $650M upfront in a deal worth up to $10.5B for 12 early-stage cancer programs.
- Why it matters: This is a BD&L, not an acquisition — Pfizer pays $650M upfront and contributes four de novo discovery programs; Innovent brings eight early-stage assets. Up to $9.85B in development, regulatory, and commercial milestones takes total potential value to $10.5B, plus double-digit royalties, with Pfizer holding global rights and co-commercialisation optionality across ADCs and multi-specific antibodies. Timed to ASCO's opening day, the deal reinforces Pfizer's strategy of plugging its approaching LOE cliff via Chinese-origin innovation — Innovent HK shares jumped ~11% on the news. Risk flag: calls to extend the COINS Act to biotech (covered in Thursday's edition) represent a live regulatory overhang on China-sourced structures like this one.
- Source: Endpoints
- More: BioSpace; Fierce Biotech;
|
|
2
|
SHINE wins European authorization for Ilumira
|
- Ilumira won European Marketing Authorization, opening a new market for non-carrier-added Lu-177 and giving SHINE another radiopharma brick in the wall.
- Why it matters: Non-carrier-added Lu-177 commands a premium over carrier-added forms due to its higher specific activity — critical for radiopharmaceutical labelling efficiency and dose consistency. European marketing authorisation gives SHINE a regulatory foothold in a supply chain where demand is outpacing capacity, driven by PSMA- and SSTR2-targeted therapies from Novartis, Eli Lilly, and others. SHINE (private) is one of few accelerator-based, non-reactor Lu-177 manufacturers; this clearance strengthens its strategic positioning ahead of potential partnerships or exit activity in a radiopharma buildout cycle.
-
Source:
PR
|
| 3 | ASCO 2026 opens: ivonescimab OS, daraxonrasib Phase 3 in focus |
- The year's biggest oncology data event opens today in Chicago (May 29 – June 2, ~40,000 attendees) with more than 7,000 abstracts — late-breaking plenary readouts are the ones to watch.
- Why it matters: Three readouts carry the most investor weight. Akeso/Summit's ivonescimab HARMONi-6 overall survival data (plenary) will test whether the PD-1/VEGF bispecific's PFS advantage over tislelizumab plus chemo translates into a survival signal — the result that would confirm it as a credible Keytruda challenger in NSCLC. Revolution Medicines presents detailed Phase 3 RASolute 302 data for daraxonrasib in pancreatic cancer on May 31 (plenary LBA5); topline already showed OS benefit and this is the readout underpinning ongoing Merck acquisition speculation. Merck's sac-TMT, a TROP2 ADC licensed from Kelun, gets a high-profile showcase that matters for Merck's post-Keytruda pipeline build.
-
Source:
BioSpace
|
Everything Else that broke
- Allogene's CEO David Chang will step down at the end of June after eight years. — Endpoints
- Seer asked the ITC to block imports of Nanomics' Proteonano kits and workstations. — PR
- Labcorp is backing a multi-institution colorectal cancer genetic-testing trial with Alliance for Clinical Trials in Oncology. — PR
- Alaw dosed patients in Phase 1a/b with AL-605 and kept AL-433 on track for first-in-human study. — PR
- Harbinger presented ASCO data supporting RESOLVE for evaluating suspected cancer in symptomatic patients. — PR
- Menarini shared Phase 1b/2 ELEVATE data for elacestrant plus capivasertib in ER+, HER2- metastatic breast cancer — 11.3-month median PFS and 88.9% disease control rate in the RP2D cohort. — PR
- PeproMene highlighted EHA oral data for BAFF-R CAR-T PMB-CT01 in B-cell lymphomas. — PR
- Philips added Disney content to pediatric MRI systems to ease scan anxiety. — Fierce Pharma
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Pfizer will pay $650M upfront to access 12 early-stage oncology programs from Innovent in a pact worth up to $10.5B. — Endpoints
-
UPMC Italy and United Imaging will install Europe’s first CE-marked uRT-linac 506c in Italy. — PR
VC / Private Financings
- No notable private financings in the last 24 hours. — PR
IPOs / Follow-Ons
- No notable IPOs or follow-ons in the last 24 hours. — PR
Academic Corner - Pathogenic germline variants identify elevated cancer risk in pediatric patients referred for genetic testing. — Nature Medicine
- Targeting claudins in cancer. — Nature RDD
- Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease. — Lancet
|
